Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate in 22q11.2 Deletion Syndrome
NCT04647500Completed
- Sponsor
- Université de Genève
- Start
- Aug 2016
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of methylphenidate in 22q11.2 deletion syndrome (22qDS) (2 arms), sponsored by Université de Genève. Primary endpoints: Conners' Continuous Performance Test, 3rd Edition, Stroop Task and 5 more. Started Aug 2016; status: completed.
02
Drugs
methylphenidate
03
Conditions
22q11.2 deletion syndrome (22qDS)
Beyond the preview
Go deeper on NCT04647500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04647500.